

**BALANCE SHEETS**

	<u>March 31, 2024</u> <u>U.S. Dollars</u> <u>Unaudited</u>
ASSETS	
CURRENT ASSETS:	
Cash and cash equivalents	1
Short-term bank deposits	-
Current maturities of LT Bank Deposits	-
Restricted short term bank deposit	-
Marketable Securities	-
Trade accounts receivable	-
Other receivables and prepaid expenses:	
Prepaid expenses	-
Deferred income taxes	-
Government authorities	-
Advances to suppliers	-
Derivative instruments	-
Intercompany balances	-
Other	-
TOTAL Other receivables and prepaid expenses	-
Inventories	-
TOTAL CURRENT ASSETS	1
Long Term Receivables and Other Assets	-
Long Term Marketable Securities	-
ROU Assets, net	-
FIXED ASSETS:	
Cost	-
Less - accumulated depreciation	-
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	-
DEFERRED INCOME TAXES	-
TOTAL ASSETS	<u>\$ 1</u>

**BALANCE SHEETS**

---

	<u>March 31, 2024</u>
	<u>U.S. Dollars</u>
	<u>Unaudited</u>
LIABILITIES AND SHAREHOLDERS' EQUITY	
CURRENT LIABILITIES:	
Short-term bank credit	\$ -
Current maturities of long-term debt	-
Accounts payable:	
Trade payables	-
Other current liabilities:	
Returns reserve	-
Due to customers	-
Intercompany balances	-
Lease Liability	-
Employees and payroll accruals	-
Current Maturities of Long Term Incentive Plan (LTIP)	-
Deferred revenue	-
Accrued income taxes	-
Legal and audit fees	-
Settlements and loss contingencies	-
Accrued expenses	-
Interest payable	-
Derivative instruments	-
Deferred taxes	-
Suppliers of property, plant and equipment	-
Payable on Purchase of treasury stock	-
Payable on Purchase of Marketable Securities	-
Other	-
TOTAL Other current liabilities	<u>-</u>
TOTAL CURRENT LIABILITIES	<u>-</u>
LONG-TERM LIABILITIES:	
Long-term debt, net of current maturities	-
Deferred income taxes	-
Derivative instruments	-
Other long-term liabilities	-
	<u>-</u>
SHAREHOLDERS' EQUITY	<u>1</u>
	<u>\$ 1</u>

---

Date of approval of the  
financial statements

---

William Coote  
VP, Chief Financial

Taro Pharma Corporation, Inc.

---

STATEMENTS OF INCOME

---

	<u>For the Year</u> <u>Ended</u> <u>March 31, 2024</u> <u>U.S. Dollars</u> <u>Unaudited</u>
Sales	\$ -
Cost of sales	<u>-</u>
Gross profit	-
Research and development	-
Selling and marketing expenses	-
Settlements and loss contingencies	-
General and administrative expenses	<u>-</u>
Operating income	-
Financing income, net	-
Other income	<u>-</u>
Income before taxes on income	-
Taxes on income	<u>-</u>
Discontinued operation	<u>-</u>
Net income for the period before subsidiaries and dividend	-
Dividend income, net	-
Subsidiaries	<u>-</u>
Net income for the period	<u><u>\$ -</u></u>

